Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wouter Haazen

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
The Lancet. Infectious Diseases|May 14, 2019
Safety and immunogenicity of a vaccine for extra-intestinal pathogenic Escherichia coli (ESTELLA): a phase 2 randomised controlled trialRobert W Frenck, John Ervin, Laurence Chu, et al.
Clinical Pharmacokinetics|June 19, 2016
Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib StudyStephan Glund, Joachim Stangier, Joanne van Ryn, et al.
The Journal of Urology|October 20, 2020
Epidemiology and O-Serotypes of Extraintestinal Pathogenic <i>Escherichia coli</i> Disease in Patients Undergoing Transrectal Ultrasound Prostate Biopsy: A Prospective Multicenter StudySteven Rosenberg, Marc Bonten, Wouter Haazen, et al.
The Journal of Urology|January 6, 2021
Reply by AuthorsSteven Rosenberg, Marc Bonten, Wouter Haazen, et al.
The Journal of Infectious Diseases|October 19, 2022
Phase 1/2a Safety and Immunogenicity of an Adenovirus 26 Vector Respiratory Syncytial Virus (RSV) Vaccine Encoding Prefusion F in Adults 18-50 Years and RSV-Seropositive Children 12-24 MonthsArabella S V Stuart, Miia Virta, Kristi Williams, et al.
The Journal of Infectious Diseases|January 5, 2021
Prevention of Respiratory Syncytial Virus Infection in Healthy Adults by a Single Immunization of Ad26.RSV.preF in a Human Challenge StudyJerald Sadoff, Els De Paepe, John DeVincenzo, et al.
Antimicrobial Agents and Chemotherapy|October 8, 2008
Minimal effects of ritonavir and efavirenz on the pharmacokinetics of raltegravirMarian Iwamoto, Larissa A Wenning, Amelia S Petry, et al.
Journal of Clinical Pharmacology|May 27, 2016
Pharmacokinetics and Pharmacodynamics of Omarigliptin, a Once-Weekly Dipeptidyl Peptidase-4 (DPP-4) Inhibitor, After Single and Multiple Doses in Healthy SubjectsRajesh Krishna, Carol Addy, Daniel Tatosian, et al.
Open Forum Infectious Diseases|September 2, 2024
A Phase 1/2a Study Evaluating Safety and Immunogenicity of Ad26.RSV.preF in RSV-seronegative Toddlers Aged 12-24 MonthsJoanne M Langley, Terry M Nolan, Mika Rämet, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
The Lancet. Infectious Diseases|May 14, 2019
Safety and immunogenicity of a vaccine for extra-intestinal pathogenic Escherichia coli (ESTELLA): a phase 2 randomised controlled trialRobert W Frenck, John Ervin, Laurence Chu, et al.
Clinical Pharmacokinetics|June 19, 2016
Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib StudyStephan Glund, Joachim Stangier, Joanne van Ryn, et al.
The Journal of Urology|October 20, 2020
Epidemiology and O-Serotypes of Extraintestinal Pathogenic <i>Escherichia coli</i> Disease in Patients Undergoing Transrectal Ultrasound Prostate Biopsy: A Prospective Multicenter StudySteven Rosenberg, Marc Bonten, Wouter Haazen, et al.
The Journal of Urology|January 6, 2021
Reply by AuthorsSteven Rosenberg, Marc Bonten, Wouter Haazen, et al.
The Journal of Infectious Diseases|October 19, 2022
Phase 1/2a Safety and Immunogenicity of an Adenovirus 26 Vector Respiratory Syncytial Virus (RSV) Vaccine Encoding Prefusion F in Adults 18-50 Years and RSV-Seropositive Children 12-24 MonthsArabella S V Stuart, Miia Virta, Kristi Williams, et al.
The Journal of Infectious Diseases|January 5, 2021
Prevention of Respiratory Syncytial Virus Infection in Healthy Adults by a Single Immunization of Ad26.RSV.preF in a Human Challenge StudyJerald Sadoff, Els De Paepe, John DeVincenzo, et al.
Antimicrobial Agents and Chemotherapy|October 8, 2008
Minimal effects of ritonavir and efavirenz on the pharmacokinetics of raltegravirMarian Iwamoto, Larissa A Wenning, Amelia S Petry, et al.
Journal of Clinical Pharmacology|May 27, 2016
Pharmacokinetics and Pharmacodynamics of Omarigliptin, a Once-Weekly Dipeptidyl Peptidase-4 (DPP-4) Inhibitor, After Single and Multiple Doses in Healthy SubjectsRajesh Krishna, Carol Addy, Daniel Tatosian, et al.
Open Forum Infectious Diseases|September 2, 2024
A Phase 1/2a Study Evaluating Safety and Immunogenicity of Ad26.RSV.preF in RSV-seronegative Toddlers Aged 12-24 MonthsJoanne M Langley, Terry M Nolan, Mika Rämet, et al.
Pageof 2